Beta Bionics, Inc. (BBNX) Q2 2025 Earnings Call Transcript

Beta Bionics reported robust Q2 2025 results, with net sales up 54% to $23.2 million and new patient starts increasing 57% to 4,934, driven by strong iLet system demand and expanding pharmacy channel adoption, which now accounts for a high 20s percentage of new starts. This performance led to a raised full-year 2025 guidance across net sales ($88M-$93M), pharmacy mix, and gross margin. The company addressed the proposed CMS rule for 2026 DME, indicating no material revenue impact from competitive bidding, while viewing the shift to a pay-as-you-go rental model as a net long-term tailwind, despite a potential minor near-term revenue headwind, as it could boost adoption and market share. Beta Bionics also highlighted pipeline progress, including the Mint patch pump targeting 2027 commercialization and advancements in its bihormonal system.

Analysis

Beta Bionics (BBNX) reported a strong second quarter for 2025, exceeding expectations with net sales growing 54% year-over-year to $23.2 million, driven by a 57% increase in new patient starts to 4,934. A key driver of this performance is the accelerating adoption of its iLet system through the pharmacy channel, which accounted for a high 20s percentage of new starts, a substantial increase from the mid-single-digit percentage in the prior year. While this strategic shift creates a transitory revenue and margin headwind by forgoing upfront pump payments, management quantifies the long-term benefit, estimating a $1 million headwind in 2025 could translate into a $9 million cumulative revenue tailwind from 2026-2028. The company's confidence is reflected in its raised full-year 2025 guidance for revenue to $88-$93 million and gross margin to 52%-55%, a lift attributed to manufacturing scale and the growing base of high-margin recurring revenue from the pharmacy channel, which more than offsets the mix shift pressure. The company also addressed the proposed 2026 CMS rule for durable medical equipment, viewing the potential shift to a pay-as-you-go rental model as a net tailwind that could accelerate pump adoption and market share gains, despite a potential single-digit percentage revenue headwind in the first year. The innovation pipeline remains a key focus, with progress on the Mint patch pump, targeting a 2027 launch, and the bihormonal system, for which preliminary PD study results are supportive. Notably, an estimated 25% of new patient starts were for off-label use in Type 2 diabetes, signaling a significant future market opportunity.

Key Decisions for Investors

• Investors should recognize the strong commercial execution evidenced by the significant Q2 beat and raised full-year guidance, validating the market's demand for the iLet system and the effectiveness of the expanded sales force.
• It is crucial to model the financial impact of the strategic shift to the pharmacy channel, accepting the near-term revenue headwind in exchange for a more predictable and financially accretive recurring revenue model in the medium- to long-term.
• Monitor the final CMS ruling on the DME payment system; while management frames the pay-as-you-go shift as a net positive, investors should assess the potential for near-term revenue recognition changes and any indirect risk from price compression on DME partners.
• Factor in the long-term optionality from the innovation pipeline, including the Mint patch pump and bihormonal system, as well as the significant, albeit off-label, traction in the Type 2 diabetes market, which represents a substantial future growth catalyst.